52North - creators of Neutrocheck®
52North develops in-vitro diagnostic and digital solutions aimed at improving the safety and effectiveness of emergency care. Their product portfolio includes Neutrocheck®, a portable blood test for identifying neutropenic sepsis risk, and ACORN™, a digital tool for remote triage in emergency cancer care. The company leverages its Aster™ platform for rapid, multiplexed cell measurement from single samples.
- Digital Health
- Healthcare Technology
- Software Only
Funding
Raised to date
$6.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer patients undergoing chemotherapy are at risk of neutropenic sepsis (NS), a life-threatening condition. Current protocols require patients experiencing any symptoms to visit the emergency room, leading to unnecessary hospital visits and delayed treatment for those truly at risk. This pathway results in delayed antibiotic administration for approximately half of patients who need it and unnecessary hospital visits for the other half.
Solution
52North provides Neutrocheck®, a point-of-care solution that enables cancer patients to monitor their risk of neutropenic sepsis at home. The system comprises a low-cost finger prick blood test and a digital platform that delivers rapid and reliable results. By measuring neutrophil count and C-reactive protein (CRP) levels, Neutrocheck® helps clinicians identify patients at genuine risk of NS, enabling timely intervention and reducing unnecessary hospital visits. The platform aims to reinvent the care pathway, making it safer, more effective, and less stressful for patients and healthcare providers.
Target Audience
The primary target audience includes cancer patients undergoing chemotherapy and their healthcare providers, specifically oncologists and nurses.
Features
- Finger-prick blood test for convenient at-home use
- Rapid measurement of neutrophil count and C-reactive protein (CRP) levels
- Digital platform for result interpretation and communication with healthcare providers
- Integrated system designed to identify patients at risk of neutropenic sepsis
- Aims to reduce unnecessary emergency room visits
- Designed to enable timely antibiotic administration when needed